Thus, further technological advancements are required to remotely control the ADCs. To overcome this problem, strategies, including decreasing the binding strength, conjugating more drugs, and targeting tumor stroma, have been applied, albeit with limited success. However, because tumors express antigens heterogeneously, greater target specificity and stable binding of noncleavable linkers in ADCs limit their antitumor effects. Antibodies linked with small-molecule drugs (i.e., antibody–drug conjugates ) are widely used in clinics as antibody-based therapeutics. Therefore, antibody-based therapies that specifically target cancer antigens can be considered ideal cancer therapies. Ideal cancer treatments specifically target and eradicate tumor cells without affecting healthy cells.
T DM1 SIDE EFFECTS SOFTWARE
Kazuhide Sato, Institute for Advanced Research, Department of Respiratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Aichi 466-8550, Japan.Įmail: Conceptualization (lead), Data curation (lead), Formal analysis (lead), Funding acquisition (lead), Investigation (lead), Methodology (equal), Project administration (lead), Resources (lead), Software (equal), Supervision (lead), Validation (lead), Visualization (lead), Writing - original draft (lead), Writing - review & editing (lead) Search for more papers by this author Nagoya University Institute for Advanced Research, S-YLC, Japan Institute of Nano-Life-Systems, Institutes of Innovation for Future Society, Nagoya University, Nagoya, JapanįOREST-Souhatsu, CREST, JST, Chiyoda-ku, Tokyo, Japan Nagoya University Institute for Advanced Research, Advanced Analytical and Diagnostic Imaging Center (AADIC)/Medical Engineering Unit (MEU), B3 Unit, Showa-ku, Nagoya, Japan
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan
0 kommentar(er)
